Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhPDGF-BB-Enhanced Wound Matrix in Head or Neck Defects Following Skin Cancer Excision
NCT06634030Phase 2Completed
- Sponsor
- Vanderbilt University Medical Center
- Start
- Apr 2025
- Primary completion
- Jul 2026
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of becaplermin in surgical wound (2 arms), sponsored by Vanderbilt University Medical Center. Primary endpoint: Time-to-Readiness for Skin Graft in Days. Started Apr 2025; status: completed.
02
Drugs
becaplermin
03
Conditions
surgical wound
Beyond the preview
Go deeper on NCT06634030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06634030.